Eskander, R. N., Sill, M., Beffa, L., Moore, R. G., Hope, J. M., Musa, F., Mannel, R. S., Shahin, M. S., Cantuaria, G. H., Girda, E., Mathews, C. A., Kavecansky, J., Leath, C. A., Gien, L. T., Hinchcliff, E., Lele, S. B., Landrum, L. M., Backes, F. J., Powell, M. A., Aghajanian, C. (2026). Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5502